FDA approves nerve-stimulation wearable as first device for adolescent IBS pain

FDA
Similar versions of the nerve-stimulation device have been authorized to reduce the symptoms of opioid withdrawal as well as for use in acupuncture. (Andrew Harnik, Associated Press)

The FDA has approved the first medical device to help reduce abdominal pain in adolescents with irritable bowel syndrome (IBS) through the use of nerve stimulation.

The IB-Stim non-surgical prescription device, developed by Innovative Health Solutions, is designed for patients between 11 and 18 years old. Placed behind the ear, the small, battery-powered device continuously emits mild electrical pulses that target certain branches and bundles of cranial nerves. After five days, the device is replaced.

According to the agency, patients can use the device for up to three consecutive weeks to help reduce functional abdominal pain associated with IBS, alongside other therapies for the syndrome.

Webinar

How ICON, Lotus, and Bioforum are Improving Study Efficiency with a Modern EDC

CROs are often at the forefront of adopting new technologies to make clinical trials more efficient. Hear how ICON, Lotus Clinical Research, and Bioforum are speeding database builds and automating reporting tasks for data management.

RELATED: FDA OKs behind-the-ear device for opioid withdrawal

Though the FDA reviewed and granted the IB-Stim a 510(k) clearance through its de novo product review pathway, the agency had previously authorized similar versions of the device. In 2017, the agency approved the NSS-2 Bridge device to reduce the symptoms of opioid withdrawal, and the first such approval was in 2014 as the Electro Auricular Device for use in acupuncture.

In a clinical study, 50 adolescent participants with IBS were randomized against a sham treatment. Those who received the device therapy saw greater improvements compared to baseline pain scores after three weeks in measurements of frequency, severity and duration.

Additionally, 52% of treated patients saw at least a 30% drop in their usual levels of pain over the same time period, while 59% reported at least a 30% drop in their worst levels of pain.

That outpaced the 30% and 26% of patients who reached the same levels while receiving the placebo treatment in their usual and worst pain scores, respectively.

Suggested Articles

The ADDF announced its second round of research awards, with a total of $6 million in new funding for diagnostic tests.

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.

Johns Hopkins researchers developed a biodegradable polymer to transport large therapies into cells—including genes and even CRISPR.